Evidence map›Paper›PMID 39866364›Full record

ArticleArchives of internal medicine research2024

Systemic Lupus Erythematous: Gene Polymorphisms, Epigenetics, Environmental, Hormonal and Nutritional Factors in the Consideration of Personalized Therapy.

Nejma Wais, Devendra K Agrawal

Abstract read
In one paragraph

Article in Archives of internal medicine research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nejma WaisDepartment of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA.
Devendra K AgrawalDepartment of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California 91766 USA.

Funding

Novel Molecular Target to Prevent Maturation Failure of Arteriovenous FistulaR01HL147662 · NHLBI · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI AGRAWAL, DEVENDRA K. · 2019 to 2022
$2.8M
Research Education Program to Promote Diversity in Immunologic and Allergic DiseasesR25AI179582 · NIAID · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI Devendra K. Agrawal · 2025 to 2026
$756k
NHLBI NIH HHS R01 HL147662NIAID NIH HHS R25 AI179582
6 · The paper itself

Abstract

Systemic Lupus Erythematosus (SLE) is a chronic illness that can affect many tissues through the production of autoantibodies. A definite etiology has not been conclusively established, but current research points to the influences which include genetic, hormonal and environmental factors. SLE is difficult to treat due to its multifactorial pathogenesis and heterogeneity in clinical manifestations. Current treatment mainly includes anti-malarial medications, glucocorticoids, and biologics, but many patients still struggle in achieving remission. Additionally, there is no definite cure for SLE as of now, which further emphasizes the need for personalized treatment approaches. We analyzed genetic polymorphisms, DNA methylation, and other environmental, hormonal and nutritional factors in the development of SLE. We considered how such factors affect the processes of the disease pathogenesis and may provide insight on targets for potential personalized therapy. In this article, we criticaly reviewed the literature for compelling evidence connecting SLE and specific genes and epigenetic changes. We also explored environmental triggers such as UV exposure, and hormonal influences on their connection to SLE, working toward understanding the disease's complex nature. A critical evaluation is presented on the use of already accredited biologics in SLE that are beneficial to patients, including anifrolumab and belimumab. The reports on many factors that may influence SLE pathophysiology, along with success with recent biologics/targeted therapies, suggest that precision medicine, tailored to individual genetic and environmental profiles, may hold promise for enhancing remission rates and quality of life for SLE patients. The findings contribute to the field by addressing the need for an integrative approach to SLE treatment and offer more evidence for the potential critical benefit of personalized management strategies that may provide long-term solutions in this challenging and complex disease.

Indexed as

Autoimmune diseaseEnvironmental factorsEpigeneticsGene polymorphismNutritional factorsPathophysiologySystemic Lupus Erythematosus

Identifiers

PMID39866364
PMCPMC11759484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.